MedPath

Study of a New Topical Natural Health Product for the Treatment of Herpes Labialis

Not Applicable
Conditions
Herpes Labialis
Registration Number
NCT02582086
Lead Sponsor
Laboratoire Boreaderme Inc.
Brief Summary

The aim of this study is to determine the safety and efficacy of a topical natural health product in comparison to placebo for the treatment of herpes labialis.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Female and male, in good health, 18 years of age or older,
  • With history of recurrent herpes labialis with at least twice a year during the past twenty-four months,
  • Agreeing not to take another treatment against cold sore, nor anti-inflammatory, antibiotics and steroids,
  • Cooperating in the study, able to be monitored at each visit, aware of the demands and duration of the controls, thus allowing perfect adherence to the established protocol,
  • Must be willing and able to participate and to provide written informed consent,
  • Female subjects of childbearing potential must have a negative pregnancy test at screening and agree to use a proper contraceptive method during the study.
Exclusion Criteria
  • Volunteers who refuse to introduce the product to be tested in its routine,
  • With a history of hypersensitivity to the type of product to be tested (e.g., products that contain essential oil),
  • Who have a history of eczema, topical dermatitis, psoriasis or significant skin anomalies on the areas to be tested,
  • Who suffer from a serious illness or health problem or a critical or progressive disease,
  • Who have taken prescription or over the counter medication that could affect skin characteristics or could bias the study (i.e. antibiotics, antihistamines, anti-inflammatories...) within 7 days prior to study beginning,
  • Who have recently acquired or who currently have significant skin pigmentation, who frequent tanning salons or foresee exposure to the sun during the study,
  • Who abuse alcohol, drugs and/or tobacco,
  • Female subjects who are pregnant, breastfeeding or expecting to become pregnant during the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Time to healing as assessed by the investigatorup to 10 days
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Evalulab Inc

🇨🇦

Montréal, Quebec, Canada

Evalulab Inc
🇨🇦Montréal, Quebec, Canada
Elisabeth EF Fiquet, M. Sc.
Contact
5143430001
efiquet@evalulab.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.